Skip to search formSkip to main contentSkip to account menu

Substrate Deprivation Therapy

Known as: Substrate Reduction Therapy 
A therapeutic procedure based on the inhibition or reduction of the biosynthesis of compounds that cannot break down in the cells.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
2014
2014
Bone disease in patients with Gaucher disease
Gaucher disease is an inborn error of metabolism due to a deficiency of the lysosomal enzyme glucocerebrosidase. As a result of… 
Review
2013
Review
2013
Therapeutic approaches for lysosomal storage diseases: a patent update.
Lysosomal Storage Diseases (LSDs) are inherited metabolic disorders caused by specific lysosomal protein deficiencies, which lead… 
2010
2010
Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
2009
2009
A new surrogate marker for CNS pathology in Niemann-Pick disease type C?
Review
2007
Review
2007
Update on treatment of lysosomal storage diseases.
Lysosomal storage diseases (LSDs) are a large group of disorders caused by a deficiency of specific enzymes responsible for the… 
Review
2007
Review
2007
Therapy for Gaucher disease: don't stop thinking about tomorrow.
Review
2007
Review
2007
[Current development and usefulness of biomarkers for Gaucher disease follow up].
2006
2006
Clinical experience with substrate reduction therapy.
2005
2005
Newborn screening for lysosomal storage disorders.
The concept of screening newborns for inherited metabolic disorders was the brainchild of Robert Guthrie, an upstate New York… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)